{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:43:13Z","timestamp":1773276193908,"version":"3.50.1"},"reference-count":56,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hematologic stem cell rescue after high-dose cytotoxic therapy is extensively used for the treatment of many hematopoietic and solid cancers. Gene marking studies suggest that occult tumor cells within the autograft may contribute to clinical relapse. To date purging of autografts contaminated with cancer cells has been unsuccessful. The selective oncolytic property of reovirus against myriad malignant histologies in in vitro, in vivo, and ex vivo systems has been previously demonstrated. In the present study we have shown that reovirus can successfully purge cancer cells within autografts. Human monocytic and myeloma cell lines as well as enriched ex vivo lymphoma, myeloma, and Waldenstro\u0308m macroglobulinemia patient tumor specimens were used in an experimental purging model. Viability of the cell lines or purified ex vivo tumor cells of diffuse large B-cell lymphoma, chronic lymphocytic leukemia, Waldenstro\u0308m macroglobulinemia, and small lymphocytic lymphoma was significantly reduced after reovirus treatment. Further, [35S]-methionine labeling and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of cellular proteins demonstrated reovirus protein synthesis and disruption of host cell protein synthesis as early as 24 hours. Admixtures of apheresis product with the abovementioned tumor cells and cell lines treated with reovirus showed complete purging of disease. In contrast, reovirus purging of enriched ex vivo multiple myeloma, Burkitt lymphoma, and follicular lymphoma was incomplete. The oncolytic action of reovirus did not affect CD34+ stem cells or their long-term colony-forming assays even after granulocyte colony-stimulating factor (G-CSF) stimulation. Our results indicate the ex vivo use of an unattenuated oncolytic virus as an attractive purging strategy for autologous stem cell transplantations. (Blood. 2003;102:377-387)<\/jats:p>","DOI":"10.1182\/blood-2002-08-2508","type":"journal-article","created":{"date-parts":[[2003,3,18]],"date-time":"2003-03-18T16:13:45Z","timestamp":1048004025000},"page":"377-387","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":53,"title":["Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation"],"prefix":"10.1182","volume":"102","author":[{"given":"Chandini M.","family":"Thirukkumaran","sequence":"first","affiliation":[{"name":"From the Calgary Laboratory Services, Calgary, AB; Department of Medicine, Tom Baker Cancer Centre, Calgary, AB; and the Department of Medicine and Oncology, University of Calgary, AB, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne M.","family":"Luider","sequence":"additional","affiliation":[{"name":"From the Calgary Laboratory Services, Calgary, AB; Department of Medicine, Tom Baker Cancer Centre, Calgary, AB; and the Department of Medicine and Oncology, University of Calgary, AB, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas A.","family":"Stewart","sequence":"additional","affiliation":[{"name":"From the Calgary Laboratory Services, Calgary, AB; Department of Medicine, Tom Baker Cancer Centre, Calgary, AB; and the Department of Medicine and Oncology, University of Calgary, AB, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Cheng","sequence":"additional","affiliation":[{"name":"From the Calgary Laboratory Services, Calgary, AB; Department of Medicine, Tom Baker Cancer Centre, Calgary, AB; and the Department of Medicine and Oncology, University of Calgary, AB, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasha M.","family":"Lupichuk","sequence":"additional","affiliation":[{"name":"From the Calgary Laboratory Services, Calgary, AB; Department of Medicine, Tom Baker Cancer Centre, Calgary, AB; and the Department of Medicine and Oncology, University of Calgary, AB, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Nodwell","sequence":"additional","affiliation":[{"name":"From the Calgary Laboratory Services, Calgary, AB; Department of Medicine, Tom Baker Cancer Centre, Calgary, AB; and the Department of Medicine and Oncology, University of Calgary, AB, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A.","family":"Russell","sequence":"additional","affiliation":[{"name":"From the Calgary Laboratory Services, Calgary, AB; Department of Medicine, Tom Baker Cancer Centre, Calgary, AB; and the Department of Medicine and Oncology, University of Calgary, AB, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwona A.","family":"Auer","sequence":"additional","affiliation":[{"name":"From the Calgary Laboratory Services, Calgary, AB; Department of Medicine, Tom Baker Cancer Centre, Calgary, AB; and the Department of Medicine and Oncology, University of Calgary, AB, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald G.","family":"Morris","sequence":"additional","affiliation":[{"name":"From the Calgary Laboratory Services, Calgary, AB; Department of Medicine, Tom Baker Cancer Centre, Calgary, AB; and the Department of Medicine and Oncology, University of Calgary, AB, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021217391198600_REF1","doi-asserted-by":"crossref","unstructured":"Armitage JO. Bone marrow transplantation in the treatment of patients with lymphoma. Blood.1989;73: 1749-1758.","DOI":"10.1182\/blood.V73.7.1749.bloodjournal7371749"},{"key":"2020021217391198600_REF2","doi-asserted-by":"crossref","unstructured":"Freedman AS, Takvorian T, Anderson KC, et al. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol.1990;8: 784-791.","DOI":"10.1200\/JCO.1990.8.5.784"},{"key":"2020021217391198600_REF3","unstructured":"Ball ED, Mills LE, Gibbons G, et al. Autologous bone marrow transplantation for acute myeloid leukemia using monoclonal antibody-purged bone marrow. Blood.1990;75: 1199-1206."},{"key":"2020021217391198600_REF4","doi-asserted-by":"crossref","unstructured":"Gribben JG, Linch DC, Singer CRJ, McMillan AK, Jarrett M, Goldstone AH. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood.1989;73: 340-344.","DOI":"10.1182\/blood.V73.1.340.340"},{"key":"2020021217391198600_REF5","doi-asserted-by":"crossref","unstructured":"Wallerstein R, Spitzer G, Dunphy F, et al. A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. J Clin Oncol.1990;8: 1782-1788.","DOI":"10.1200\/JCO.1990.8.11.1782"},{"key":"2020021217391198600_REF6","unstructured":"Eapen M. Report on state of the art in blood and marrow transplantation\u2014the IBMTR\/ABMTR summary slide with guide. Int Bone Marrow Transplant Registry Autologous Blood Marrow Transplant Registry.2002;9: 1-11."},{"key":"2020021217391198600_REF7","doi-asserted-by":"crossref","unstructured":"Gratwohl A, Passweg J, Baldomero H, Urbano-Ispizua A. Hematopoietic stem cell transplantation activity in Europe. Bone Marrow Transplant.2001;27: 899-916.","DOI":"10.1038\/sj.bmt.1702995"},{"key":"2020021217391198600_REF8","unstructured":"Rizzo JD. New summary slides show current trends in BMT. Int Bone Marrow Transplant Registry Autologous Blood Marrow Transplant Registry.1998;5: 4-10."},{"key":"2020021217391198600_REF9","unstructured":"Heslop HE, Rill DR, Horwitz EM, Contant CF, Krance RA, Brenner MK. Gene marking to assess tumor contamination in stem cell grafts for acute myeloid leukemia. In: Dicke KA, Keating A, eds. Autologous Blood and Marrow Transplantation: Proceedings of the Ninth International Symposium. Arlington, TX: 1999: 513-520."},{"key":"2020021217391198600_REF10","doi-asserted-by":"crossref","unstructured":"Deisseroth AB, Zu Z, Claxton D, et al. Genetic markers shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood.1994;83: 3068-3076.","DOI":"10.1182\/blood.V83.10.3068.3068"},{"key":"2020021217391198600_REF11","doi-asserted-by":"crossref","unstructured":"Rill DR, Santana VM, Roberts WM, et al. Direct demonstration that autologous bone barrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood.1994;84: 380-383.","DOI":"10.1182\/blood.V84.2.380.380"},{"key":"2020021217391198600_REF12","doi-asserted-by":"crossref","unstructured":"Lemoli RM, Gasparetto C, Scheinberg DA, Moore MA, Clarkson BD, Gulati SC. Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination. Blood.1991;77: 1829-1836.","DOI":"10.1182\/blood.V77.8.1829.1829"},{"key":"2020021217391198600_REF13","doi-asserted-by":"crossref","unstructured":"Leung W, Cheng AR, Klann RC, et al. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Bone Marrow Transplant.1998;22: 971-979.","DOI":"10.1038\/sj.bmt.1701471"},{"key":"2020021217391198600_REF14","doi-asserted-by":"crossref","unstructured":"Tsujino I, Anderson GS, Sieber F. Postirradiation hyperthermia selectively potentiates the merocyanine 540-sensitized photoinacitvation of small cell lung cancer cells. Photochem Photobiol.2001;73: 191-198.","DOI":"10.1562\/0031-8655(2001)073<0191:PHSPTM>2.0.CO;2"},{"key":"2020021217391198600_REF15","doi-asserted-by":"crossref","unstructured":"Brasseur N, Menard I, Forget A, et al. Eradication of multiple myeloma and breast cancer cells by TH9402-mediated photodynamic therapy: implication for clinical ex vivo purging of autologous stem cell transplants. Photochem Photobiol.2000;72: 780-787.","DOI":"10.1562\/0031-8655(2000)072<0780:EOMMAB>2.0.CO;2"},{"key":"2020021217391198600_REF16","doi-asserted-by":"crossref","unstructured":"Villeneuve L. Ex vivo photodynamic purging in chronic myelogenous leukaemia and other neoplasias with rhodamine derivatives. Biotechnol Appl Biochem.1999;30: 1-17.","DOI":"10.1111\/j.1470-8744.1999.tb01153.x"},{"key":"2020021217391198600_REF17","unstructured":"Meck MM, Wierdl M, Wagner LM, et al. A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11. Cancer Res.2001;61: 5083-5089."},{"key":"2020021217391198600_REF18","doi-asserted-by":"crossref","unstructured":"Keir M, Fiddes R, Biggs JC, Kearney PP. Sensitivity of c-erbB positive cells to a ligand toxin and its utility in purging breast cancer cells from peripheral blood stem cell (PBSC) collections. Stem Cells.2000;18: 422-427.","DOI":"10.1634\/stemcells.18-6-422"},{"key":"2020021217391198600_REF19","unstructured":"La Casse EC, Bray MR, Patterson B, et al. Shiga like Toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34+ hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation. Blood.1999;94: 2901-2910."},{"key":"2020021217391198600_REF20","unstructured":"Wu A, Mazumder A, Martuza RL, et al. Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation. Cancer Res.2001;61: 3009-3015."},{"key":"2020021217391198600_REF21","doi-asserted-by":"crossref","unstructured":"Gorin NC, Aegerter P, Auvert B, et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood.1990;75: 1606-1614.","DOI":"10.1182\/blood.V75.8.1606.1606"},{"key":"2020021217391198600_REF22","doi-asserted-by":"crossref","unstructured":"Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med.1991;325: 1525-1533.","DOI":"10.1056\/NEJM199111283252201"},{"key":"2020021217391198600_REF23","doi-asserted-by":"crossref","unstructured":"Sharp JG, Kessinger A, Mann S, et al. Outcome of a high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol.1996;14: 214-217.","DOI":"10.1200\/JCO.1996.14.1.214"},{"key":"2020021217391198600_REF24","doi-asserted-by":"crossref","unstructured":"Spyridonidis A, Schmidt M, Bernhardt W, et al. Purging of mammary carcinoma cells during ex vivo culture of CD 34+ hematopoietic progenitor cells with recombinant immunotoxins. Blood.1998;91: 1820-1827.","DOI":"10.1182\/blood.V91.5.1820"},{"key":"2020021217391198600_REF25","unstructured":"Tyler KL, Fields BN. Reoviruses. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. Philadelphia, PA: Lippincott-Raven; 1996: 1597-1623."},{"key":"2020021217391198600_REF26","unstructured":"Nibert ML, Schiff LA, Fields BN. Reoviruses and their replication. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. Philadelphia, PA: Lippincott-Raven; 1996: 1557-1596."},{"key":"2020021217391198600_REF27","doi-asserted-by":"crossref","unstructured":"Strong JE, Coffey MC, Tang D, Sabinin P, Lee PWK. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J.1998;17: 3351-3362.","DOI":"10.1093\/emboj\/17.12.3351"},{"key":"2020021217391198600_REF28","doi-asserted-by":"crossref","unstructured":"Coffey MC, Strong JM, Forsyth PA, Lee PWK. Reovirus therapy of tumors with activated ras pathway. Science.1998;282: 1332-1334.","DOI":"10.1126\/science.282.5392.1332"},{"key":"2020021217391198600_REF29","doi-asserted-by":"crossref","unstructured":"Wilcox ME, Yang W, Senger D, et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst.2001;93: 903-912.","DOI":"10.1093\/jnci\/93.12.903"},{"key":"2020021217391198600_REF30","unstructured":"Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossakowska A, Lee PKW. Oncolytic reovirus against ovarian and colon cancer. Cancer Res.2002;62: 1696-1701."},{"key":"2020021217391198600_REF31","doi-asserted-by":"crossref","unstructured":"Norman KL, Coffey MC, Hirasawa K, et al. Reovirus oncolysis of human breast cancer. Hum Gene Ther.2002;13: 641-652.","DOI":"10.1089\/10430340252837233"},{"key":"2020021217391198600_REF32","unstructured":"Nodwell M, Thirukkumaran C, Luider J, et al. Reovirus as a novel prostate cancer therapeutic [abstract]. Proc AACR.2000;41: 122."},{"key":"2020021217391198600_REF33","doi-asserted-by":"crossref","unstructured":"Alain T, Hirasawa K, Pon KJ, et al. Reovirus therapy of lymphoid malignancies. Blood.2002; 100: 4146-4153.","DOI":"10.1182\/blood-2002-02-0503"},{"key":"2020021217391198600_REF34","doi-asserted-by":"crossref","unstructured":"Smith RE, Zweerink HJ, Jocklik WK. Polypeptide components of virions, top component and scores of reovirus type 3. Virology.1969;39: 791-810.","DOI":"10.1016\/0042-6822(69)90017-8"},{"key":"2020021217391198600_REF35","doi-asserted-by":"crossref","unstructured":"Lee PW, Hayes EC, Joklik WK. Protein sigma 1 is the reovirus cell attachment protein. Virology.1981;108: 138-163.","DOI":"10.1016\/0042-6822(81)90535-3"},{"key":"2020021217391198600_REF36","doi-asserted-by":"crossref","unstructured":"Keeney M, Chin-Yee I, Weir K, Popma J, Nayar R, Sutherland DR. Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. Int Soc Hematother Graft Eng Cytometry.1998;34: 61-70.","DOI":"10.1002\/(SICI)1097-0320(19980415)34:2<61::AID-CYTO1>3.0.CO;2-F"},{"key":"2020021217391198600_REF37","doi-asserted-by":"crossref","unstructured":"Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD 34+ cell determination by flow cytometry. J Hematother.1996;5: 213-226.","DOI":"10.1089\/scd.1.1996.5.213"},{"key":"2020021217391198600_REF38","unstructured":"Gorin NC. Cryopreservation and storage of stem cells. In: Areman EM, Deeg HJ, Sacher RA, eds. Bone Marrow and Stem Cell Processing: A Manual of Current Techniques. Philadelphia, PA: FA Davis; 1992: 292-362."},{"key":"2020021217391198600_REF39","doi-asserted-by":"crossref","unstructured":"Gil J, Alcami J, Esteban M. Activation of Nf-kB by the dsRNA-dependent protein kinase, PKR involves the IkB kinase complex. Oncogene.2000; 19: 1369-1378.","DOI":"10.1038\/sj.onc.1203448"},{"key":"2020021217391198600_REF40","doi-asserted-by":"crossref","unstructured":"Didsbury J, Weber RF, Bokoch GM, Evans T, Snyderman R. rac, a novel ras-related family of proteins that are botulinum toxin substrates. J Biol Chem.1989:264: 16378-16382.","DOI":"10.1016\/S0021-9258(19)84716-6"},{"key":"2020021217391198600_REF41","doi-asserted-by":"crossref","unstructured":"Kalakonda N, Rothwell DG, Scarffe JH, Norton JD. Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation. Blood.2001;98: 1555-1560.","DOI":"10.1182\/blood.V98.5.1555"},{"key":"2020021217391198600_REF42","doi-asserted-by":"crossref","unstructured":"Lui P, Leong T, Quam L, et al. Activating mutations of N-and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group phase III clinical trial. Blood.1996;88: 2699-2706.","DOI":"10.1182\/blood.V88.7.2699.bloodjournal8872699"},{"key":"2020021217391198600_REF43","doi-asserted-by":"crossref","unstructured":"Bezieau S, Devilder MC, Avet-Loiseau H, et al. High incidence of N and K-ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat.2001;18: 212-224.","DOI":"10.1002\/humu.1177"},{"key":"2020021217391198600_REF44","doi-asserted-by":"crossref","unstructured":"Villunger A, Egle A, Kos M, et al. Functional granulocyte\/macrophage colony stimulating factor receptor is constitutively expressed on neo-plastic plasma cells and mediates tumour cell longevity. Br J Haematol.1998;102: 1069-1080.","DOI":"10.1046\/j.1365-2141.1998.00880.x"},{"key":"2020021217391198600_REF45","doi-asserted-by":"crossref","unstructured":"Cooper BW, Moss TJ, Ross AA, Ybanez J, Lazarus HM. Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patient with metastatic breast cancer. J Clin Oncol.1998; 16: 3509-3517.","DOI":"10.1200\/JCO.1998.16.11.3509"},{"key":"2020021217391198600_REF46","doi-asserted-by":"crossref","unstructured":"Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple protooncogenes in B-cell diffuse large-cell lymphomas. Nature.2001;412: 341-346.","DOI":"10.1038\/35085588"},{"key":"2020021217391198600_REF47","doi-asserted-by":"crossref","unstructured":"Popescu NC, Amsbaugh SC, DiPaolo JA, Tronick SR, Aaronson SA, Swan DC. Chromosomal localization of three human ras genes by in situ molecular hybridization. Somat Cell Mol Genet.1985;11: 149-155.","DOI":"10.1007\/BF01534703"},{"key":"2020021217391198600_REF48","doi-asserted-by":"crossref","unstructured":"Tricoli JV, Rall LB, Scott J, Bell GI, Shows TB. Localization of insulin-like growth factor genes to human chromosomes 11 and 12. Nature.1984; 310: 784-786.","DOI":"10.1038\/310784a0"},{"key":"2020021217391198600_REF49","doi-asserted-by":"crossref","unstructured":"Gulbins E, Brenner B, Schlottmann K, et al. Activation of Ras-signaling pathway by the CD 40 receptor. J Immunol.1996;157: 2844-2850.","DOI":"10.4049\/jimmunol.157.7.2844"},{"key":"2020021217391198600_REF50","doi-asserted-by":"crossref","unstructured":"Schattner EJ. Cd 40 ligand in cell pathogenesis and therapy. Leuk Lymphoma.2000;37: 461-472.","DOI":"10.3109\/10428190009058499"},{"key":"2020021217391198600_REF51","doi-asserted-by":"crossref","unstructured":"George A, Kost SI, Witzleben CL, Cebra JJ, Rubin DH. Reovirus induced liver disease in severe combine immunodeficient (SCID) mice: a model for the study of viral infection, pathogenesis, and clearance. J Exp Med.1990;171: 929-934.","DOI":"10.1084\/jem.171.3.929"},{"key":"2020021217391198600_REF52","unstructured":"Morris DG, Forsyth PA, Patterson AH, et al. A phase I clinical trail evaluating intralesional Reolysin (reovirus) in histologically confirmed malignancies [abstract]. Proc ASCO.2002;21: 24a."},{"key":"2020021217391198600_REF53","unstructured":"Lillo R, Ramirez M, Alvarez A, et al. Efficient and non-toxic adenoviral purging method for autologous transplantation in breast cancer patients. Cancer Res.2002;62: 5013-5018."},{"key":"2020021217391198600_REF54","doi-asserted-by":"crossref","unstructured":"Hirai M, LaFace D, Robinson S, et al. Ex vivo purging by adenoviral p53 gene therapy does not affect NOD-SCID repopulating activity of human CD 34+ cells. Cancer Gene Ther.2001;8: 936-947.","DOI":"10.1038\/sj.cgt.7700390"},{"key":"2020021217391198600_REF55","unstructured":"Wagner LM, Guichard SM, Burger RA, et al. Effi-cacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients. Cancer Res.2002; 62: 5001-5007."},{"key":"2020021217391198600_REF56","doi-asserted-by":"crossref","unstructured":"Stojdl DF, Lichty B, Knowles S, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med.2000;6: 821-825.","DOI":"10.1038\/77558"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/1\/377\/1688860\/h81303000377.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/1\/377\/1688860\/h81303000377.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T13:56:07Z","timestamp":1704808567000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/102\/1\/377\/16836\/Reovirus-oncolysis-as-a-novel-purging-strategy-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,7,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-08-2508","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7,1]]}}}